Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: infliximab

Tips for Transitioning Patients from Pediatric to Adult Rheumatology Care

Sarah D. Bayefsky, MD, Kimberly DeQuattro, MD, & Rebecca E. Sadun, MD, PhD  |  October 14, 2021

Approximately 50% of young adult patients with childhood-onset rheumatic diseases become lost to follow-up within the first year of transferring to adult rheumatology care, mirroring the statistics of other subspecialties.1,2 One of the challenges cited most consistently by young adult patients and their families relates to differences between rheumatology care delivery in the pediatric and…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:adalimumabPsoriatic Arthritisupadacitinib

Psoriatic Arthritis Treatment Update

Mary Choy, PharmD, BCGP, FASHP  |  October 13, 2021

About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA…

Filed under:Clinical Criteria/GuidelinesConditionsDrug UpdatesPsoriatic Arthritis Tagged with:PsA Resource CenterPsoriatic Arthritis

The Latest Psoriatic Arthritis Management Insights

Jason Liebowitz, MD, FACR  |  October 11, 2021

An overview of the research to date and the ways in which such evidence can be used to guide the treatment of patients was presented at the 2019 ACR/ARP Annual Meeting in a session titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater…

Filed under:ConditionsPsoriatic Arthritis Tagged with:Psoriatic Arthritis

Live Varicella Zoster Vaccine Safe, Effective with TNF Inhibitors

Lisa Rapaport  |  October 6, 2021

(Reuters Health)—Adults 50 years and older who take tumor necrosis factor inhibitors (TNFi’s) for a range of inflammatory disorders can receive effective protection from shingles with a live varicella zoster vaccine, a clinical trial suggests.1 Researchers randomized 617 participants receiving TNFi’s in a 1:1 ratio to receive either the Zostavax live varicella zoster vaccine or…

Filed under:Biologics/DMARDsDrug Updates Tagged with:live vaccinevaccinevaricella zoster vaccinevaricella zoster virus

Case Report: Sarcoidosis in Patient with History of IgG4-Related Disease

Veronica Matto, DO, Rajshri Shah, MD, Jie Ouyang, MD, PhD, Cory Perugino, DO, & Joseph J. LaConti, MD, PhD  |  September 14, 2021

Sarcoidosis and IgG4-related disease (IgG4-RD) are both immune-mediated, often multi-organ, diseases of uncertain etiology capable of presenting with diverse clinical manifestations. Many clinical features are common to both conditions, including hypergammaglobulinemia, the ability to form inflammatory masses and involvement of the lymph nodes, lacrimal glands, salivary glands, meninges and lungs. Although imaging modalities, such as…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:IgG4 related diseaseSarcoidosis

20 Years of RA Data: First-Line Biologic & Targeted Synthetic DMARD Trends

Michele B. Kaufman, PharmD, BCGP  |  September 1, 2021

Data from a single-center registry shines light on 20 years of trends in first-line, biologic disease-modifying anti-rheumatic drug prescriptions for patients with rheumatoid arthritis.

Filed under:Biologics/DMARDsDrug Updates Tagged with:biologic drugsEULARRheumatoid Arthritis (RA)trends

Updates in Juvenile Dermatomyositis: Pathogenesis & Patient Care

Jason Liebowitz, MD, FACR  |  July 17, 2021

Experts provided an update on juvenile dermatomyositis, discussing patient care, treatment options and the pathogenesis of disease.

Filed under:ConditionsMeeting Reports Tagged with:juvenile dermatomyositisPathogenesisPediatric RheumatologyPediatric Rheumatology SymposiumPRSYM

Manifestations of JIA: JIA-Associated Uveitis, sJIA & Lung Involvement in sJIA

Jason Liebowitz, MD, FACR  |  July 16, 2021

JIA can manifest in a variety of ways. Experts discuss the implications of uveitis, systemic disease and lung involvement in sJIA.

Filed under:ConditionsMeeting Reports Tagged with:eyesJIA-associated uveitisjuvenile idiopathic arthritis (JIA)lungsPediatric RheumatologyPediatric Rheumatology SymposiumPRSYMsJIAsJIA-associated lung disease

High Cost of Specialty Drugs Demands Action

Mary Beth Nierengarten  |  July 6, 2021

Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.

Filed under:Legislation & AdvocacyPractice Support Tagged with:drug pricingpharmacy benefit managers (PBMs)

Insight into the Biosimilar Prescribing Habits of Rheumatologists

Michele B. Kaufman, PharmD, BCGP  |  June 23, 2021

The use of biosimilar treatments is increasing, according to surveys conducted in 2018 and 2020 of rheumatologists from eight countries. In the two-year period, Japan had the largest increase in biosimilar prescriptions, with only 6% of surveyed rheumatologists reporting they prefer prescribing originator biologic agents.

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsInternationalprescriptionprescription habitsrheumatologists

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 41
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences